-
You must submit the settlement "Proof" form attached below, in order to participate in this settlement. There is a strict deadline of August 16, 2021 by which all claims must be submitted. The instructions for submitting are included in the "Proof" and the "Notice" files attached below for your download. DO NOT SEND THE FORMS TO THE SHAREHOLDERS FOUNDATION, INC.
-
To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Lawsuit Overview
Settlement Overview
You must register to view and download the Settlement Notice and Settlement Proof.
February 25, 2021 - The court preliminarily approved the settlement.
February 1, 2021 - A stipulation of settlement was filed by the parties.
July 13, 2020 - The Court of Appeals affirmed in part and reversed in part the court's dismissal order.
March 14, 2019 - A notice appealing the court's dismissal order was filed.
February 13, 2019 - The court granted the defendants' motion to dismiss.
July 31, 2018 - A motion to dismiss the second amended was filed.
May 4, 2018 - A second amended complaint was filed.
March 29, 2018 - The court granted the defendants' motion to dismiss. The plaintiffs were given leave to amend the complaint.
July 14, 2017 - A motion to dismiss the corrected amended complaint was filed.
November 10, 2016 - A corrected amended complaint was filed.
October 31, 2016 - An amended complaint was filed.
May 12, 2016 - An investor in shares of NewLink Genetics Corp (NASDAQ: NLNK) filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by NewLink Genetics Corp in connection with certain allegedly false and misleading statements made between September 17, 2013 and May 9, 2016.
According to the complaint the plaintiff alleges on behalf of purchasers of NewLink Genetics Corp (NASDAQ: NLNK) common shares between September 17, 2013 and May 9, 2016, that the defendants violated Federal Securities Laws.
More specifically, the plaintiff claims that between September 17, 2013 and May 9, 2016 the defendants made false and/or misleading statements and/or failed to disclose that the Company’s algenpantucel-L treatment was ineffective and potentially harmful to patients, and that as a result of the foregoing, NewLink Genetics Corp’s public statements were materially false and misleading at all relevant times.
On February 29, 2016, NewLink Genetics Corp provided an operational update and reported its fourth quarter and year end 2015 financial results. NewLink Genetics Corp reported that its annual Total Revenue declined from $172.59 million in 2014 to $68.50 million in 2015 and that its Net Income of $96.02 million in 2014 declined to a Net Loss of $40.38 million in 2015.
On April 29, 2016, NewLink Genetics Corp reported its first quarter 2016 financial results. NewLink Genetics Corp announced that its first quarter Total Revenue declined from $39.20 million for the first quarter 2014 to $5.71 million for the first quarter 2015 and that its Net Income of $11.19 million for the first quarter in 2014 turned into a Net Loss of $23.72 million for the first quarter 2015.
On May 09, 2016, NewLink Genetics Corp (NASDAQ: NLNK) announced the results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer. NewLink Genetics Corp said that the IMPRESS Phase 3 study of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint.
Shares of NewLink Genetics Corp (NASDAQ: NLNK) declined from $54.24 per share in September 2015 to as low as $9.23 per share on May 12, 2016.